glp-1 receptor agonists alternatives to ozempic PDB-101: Molecule of the Month: Ozempic Alternatives: GLP-1 Options &
Description
The TECOS trial showed no difference between the placebo and a sitagliptin group (Table 2) [47,48,49]
Furthermore, in a phase 2 trial in people with MASLD, 24 weeks of pemvidutide resulted in a relative reduction in liver fat content up to 76% with the 2.4 mg dose vs
Advances in Experimental Medicine and Biology, 1328, 513-522
Tolerability: Tolerability: While the side effect profile of incretin mimetics is relatively mild (low rates of severe AEs
Second-line treatments include basal insulin, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RA), sodiumglucose cotransporter 2 inhibitors (SGLT2-I), sulfonylureas (SU), or thiazolidinediones (TZD)
